Drug intelligence / Profile preview

Tisopurine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Tisopurine, also known as thiopurinol, is a small molecule drug primarily used in the treatment of gout and hyperuricemia. It functions as a xanthine oxidase inhibitor, reducing the production of uric acid in the body. It is a purine analogue. Historically, it has been associated with adverse effects such as acute hepatitis and agranulocytosis.

Brand names: Exuracid
Other names: Tisopurina4-Mercaptopyrazolo[3,4-d]pyrimidine1,7-dihydropyrazolo[3,4-d]pyrimidine-4-thione1,2-Dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-thione

Targets

XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on Tisopurine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tisopurine.

Explore the full profile